Heron Therapeutics (NASDAQ:HRTX) Receives Buy Rating from Needham & Company LLC

Needham & Company LLC reiterated their buy rating on shares of Heron Therapeutics (NASDAQ:HRTX) in a report published on Wednesday, Benzinga reports. They currently have a $5.00 price objective on the biotechnology company’s stock.

Other equities research analysts have also recently issued research reports about the company. StockNews.com raised Heron Therapeutics from a sell rating to a hold rating in a research note on Tuesday, January 16th. Capital One Financial assumed coverage on shares of Heron Therapeutics in a report on Tuesday, April 23rd. They set an overweight rating and a $6.00 price target on the stock.

Heron Therapeutics Stock Down 4.3 %

Shares of HRTX traded down $0.13 during mid-day trading on Wednesday, reaching $2.88. The company’s stock had a trading volume of 267,065 shares, compared to its average volume of 2,767,171. Heron Therapeutics has a 1 year low of $0.50 and a 1 year high of $3.22. The company has a market cap of $433.83 million, a price-to-earnings ratio of -3.42 and a beta of 1.73. The business has a fifty day moving average of $2.73 and a 200 day moving average of $2.09.

Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings results on Tuesday, March 12th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.08. The company had revenue of $34.23 million during the quarter, compared to analysts’ expectations of $30.98 million. On average, analysts predict that Heron Therapeutics will post -0.24 earnings per share for the current year.

Institutional Trading of Heron Therapeutics

Several large investors have recently modified their holdings of the company. Headlands Technologies LLC acquired a new stake in shares of Heron Therapeutics in the first quarter valued at about $30,000. Susquehanna Fundamental Investments LLC acquired a new position in shares of Heron Therapeutics during the first quarter worth approximately $32,000. Victory Capital Management Inc. grew its stake in shares of Heron Therapeutics by 30.2% in the fourth quarter. Victory Capital Management Inc. now owns 19,929 shares of the biotechnology company’s stock worth $34,000 after acquiring an additional 4,617 shares during the last quarter. ACT Advisors LLC. acquired a new position in Heron Therapeutics during the 4th quarter valued at $38,000. Finally, Diversified Trust Co bought a new stake in Heron Therapeutics in the 1st quarter valued at $66,000. 80.01% of the stock is owned by institutional investors.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.